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Sub-cutaneous immunotherapy is an effective treatment for allergy. It works by helping to modify or re-balance an
individual’s immune response to allergens and its efficacy is greatly improved by the use of adjuvants, most
commonly, aluminium hydroxide. Aluminium salts have been used in allergy therapy for many decades and are
assumed to be safe with few established side-effects. This assumption belies their potency as adjuvants and their
potential for biological reactivity both at injection sites and elsewhere in the body. There are very few data
purporting to the safety of aluminium adjuvants in allergy immunotherapy and particularly so in relation to longer
term health effects. There are, if only few, published reports of adverse events following allergy immunotherapy
and aluminium adjuvants are the prime suspects in the majority of such incidents. Aluminium adjuvants are clearly
capable of initiating unwanted side effects in recipients of immunotherapy and while there is as yet no evidence
that such are commonplace it is complacent to consider aluminium salts as harmless constituents of allergy
therapies. Future research should establish the safety of the use of aluminium adjuvants in sub-cutaneous allergy
immunotherapy.
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Aluminium salts are the adjuvant of choice in
immunotherapy
Aluminium-based adjuvants are the most commonly used
adjuvant in sub-cutaneous allergy immunotherapy (SCIT)
[1]. Approximately 75% of all such adjuvant-based ther-
apies include an aluminium salt. In parallel with the use
of aluminium-based adjuvants in vaccinations these ad-
juvants have been in use in allergy immunotherapies for
over 80 years [2]. In allergy immunotherapy injections
are sub-cutaneous and each injection includes between
0.1 and 1.25 mg of aluminium adjuvant. Allergy-specific
immunotherapy can involve as many as 15 injections of
aluminium adjuvant in a year and a treatment may be
continued for 3 to 5 years or even longer, sometimes for
the life-time of a patient [3]. Individuals may receive
therapies against several allergens simultaneously and
will be subject to parallel courses of such a dosing regimen
(Table 1). Aluminium salts are the adjuvant of choice in
both vaccinations and allergy immunotherapies because ofCorrespondence: c.exley@keele.ac.uk
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stated.their efficacy in promoting immune reactions to anti-
gens (preventative therapy) and modifying the immune
response to allergens (tolerance therapy) respectively.
While the detailed mechanisms of their activities as ad-
juvants remain to be elucidated [4] their immunopo-
tency is testimony to their biological availability and
biological reactivity at injection sites and elsewhere in
the body. Contrary to the view of a recent otherwise
informed commentary [5] aluminium adjuvants are not
‘harmless salts’! They are far from being benign partici-
pants in vaccination and immunotherapy and their reac-
tivity’s have been associated with adverse events in the
recipients of such therapies. Adverse reactions to alu-
minium adjuvants might have been avoided if there had
been a requirement to demonstrate the safety of their
use in humans. However, no such regulations exist and
the amount of aluminium salt which is included as an
adjuvant is wholly determined by its immuno-efficacy in
tandem with the respective antigen or allergen. Indeed it
is an anomaly of many trials of the safety of aluminium-
adjuvanted vaccines and immunotherapies that the (essen-
tially toxic) aluminium adjuvant is considered to be the
appropriate placebo in such clinical trials [6].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Table 1 Typical dosing regimens used in sub-cutaneous allergy immunotherapy
Context Criteria Range
First year Range of number of injections for up dosing to a maintenance dose 4 to 16 injections [7-10]
Range of number of injections for remaining first year maintenance course 4 to 12 injections [7-10]
Subsequent years Range of number of injections for subsequent annual maintenance courses 6 to 12 injections [7-10]
Recommended number of years of treatment 3 to 5 years [11,12]
Whole course Range of number of injections for 3 years treatment for a single allergen Up to 54 injections
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The safety of aluminium adjuvants used in vaccination is
under increasing scrutiny and one serious disease, a
neuromuscular disorder called macrophagic myofasciitis,
is attributed to the persistence of aluminium salts at
injections sites in muscle [13]. Established links with
other more common conditions such as chronic fatigue
syndrome [14] and autoimmune disease [15] are burgeon-
ing though the incidences of adverse events remain a very
small percentage of any vaccinated population. Herein
it is already noted that in allergy immunotherapy not
only the absolute number of injections of aluminium
adjuvants but also their frequency, for example one a
month or more (Table 1), often far exceeds that received
through vaccinations. If the safety of aluminium adju-
vants used in vaccinations is open to question then the
safety of the same adjuvants used more frequently and
in greater numbers in allergy immunotherapy must also
be in question. While adverse reactions in individuals
receiving allergy immunotherapy have been reported in
the scientific and medical literature these reports are
relatively few and far between [16,17]. Reactions include;
foreign body granulomas [18], urticaria [19], sub-cutaneous
sarcoidosis [20], progressive circumscribed sclerosis [21],
sub-cutaneous nodules [22] and cutaneous-sub-cutaneous
pseudolymphoma [23]. The actual incidence of adverse
events such as the aforementioned is unknown and while
the European Medicines Agency (EMA) lists as many as
32 adverse reactions to immunotherapy ranging from dis-
colouration of the skin to encephalopathy their informa-
tion cannot be verified as the data were not taken from an
openly available peer-reviewed resource [24].
Toxicity of aluminium adjuvants
To appreciate the safety issues which relate to the use of
aluminium adjuvants in allergy immunotherapy we need
an understanding of what happens to the injected alumin-
ium salt. We need to consider the biological availability of
aluminium both at the injection site and, as a consequence
of the transport of both dissolved and particulate alumin-
ium, beyond the immediate vicinity of the injection, for
example in the lymph nodes. Details of the bioinorganic
chemistry of aluminium adjuvants have been reviewed
recently [4] and herein it is suffice to summarise such asthe biological chemistry of the free aluminium cation,
Al3+(aq), which is the principal antagonist in aluminium
toxicity [25]. Aluminium adjuvants, as sparingly soluble
particulates, can be considered as sources of biologically
available Al3+(aq). How then could a sub-cutaneous source
of biologically available Al3+(aq) be responsible for adverse
events or reactions in allergy immunotherapy?
Aluminium body burden
The, perhaps, simplest scenario would be that aluminium
adjuvants contribute directly and significantly to an indi-
vidual’s body burden of aluminium. The latter has recently
been defined as the sum of aluminium atoms associated
with the human body at any one moment in time [26].
Under this redefinition each injection of an aluminium
adjuvant will contribute up to 1.25 mg of aluminium to
the body burden of aluminium at the time of the injec-
tion. It is important to recognise that the body burden
of aluminium is not evenly distributed throughout the
body mass and that aluminium will be found as focal
accumulations determined by the form of aluminium at
exposure and its route of entry into the body [27]. By way
of an example, evidence is beginning to demonstrate that
aluminium administered as adjuvant may be phagocytosed
as particulates by infiltrating cells and transported to dis-
tant and specific sites in the body including the lymph
nodes but also into the brain [28]. However, contrary to
burgeoning scientific evidence it is common practice by
regulatory bodies, such as the European Food Standards
Agency (EFSA) [29] or the previously mentioned EMA
[24], to apply a safety criterion known as a tolerable
weekly intake (TWI) to, almost universally, confirm the
innocuous nature of all forms of human exposure to
aluminium. This criterion, based wholly on the results
of animal studies, assumes that all exposures to alumin-
ium are ‘biochemically equal’ and that the route of expos-
ure and the form of aluminium involved are unimportant.
Nothing could be further from the truth where human ex-
posure to aluminium is concerned [26]. A single injection
of 1 mg of aluminium adjuvant will add 1 mg of alumin-
ium to the body burden but this mg of aluminium will dis-
tribute throughout the body according to myriad different
influences beginning with those occurring at the injection
site [4]. Multiple injections of aluminium adjuvant over
relatively short time periods, for example 15 injections
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therapies (Table 1), could result in significant focal accu-
mulations of aluminium at single target sites and
thereby present the possibility of aluminium toxicity at
such sites. Allergy immunotherapy with aluminium ad-
juvants will contribute significantly to the aluminium
body burden of the recipient and because of the nature
of the route of exposure it is highly likely that the fate of
a significant proportion of the adjuvant aluminium will be
focal accumulations with the potential to exert a form of
toxicity.
Aluminium the antigen
A second scenario whereby aluminium adjuvants in
allergy immunotherapies might contribute towards ad-
verse reactions to such therapies is related to the known
antigenicity of aluminium [30]. It is perhaps less well
appreciated that in addition to being an effective adju-
vant it has also been shown that aluminium can act as
an antigen. Thus, aluminium adjuvants in modifying the
body’s immune response to allergens in immunotherapy
may additionally sensitise the body to the presence of
aluminium. The result is that following injection of an
adjuvant-allergen therapy the body develops a memory
of the exposure to aluminium. Subsequent multiple in-
jections reinforce this memory and raises the possibility
that the body is sensitised to not only the aluminium
injected as adjuvant but potentially all body stores of
aluminium. The body burden of aluminium becomes an
immunological target and one which unfortunately the
machinery of immunity is unable to deal with as it
might ‘normal’ allergens/antigens. When aluminium the
adjuvant is simultaneously aluminium the antigen there
is the possibility that a relatively small exposure to alu-
minium, as might occur following a single injection of
aluminium adjuvant in immunotherapy, could instigate
a cascade of reactions whereby aluminium throughout
the body is recruited to produce a significant immune/
inflammatory-like response. The severity of such a re-
sponse would depend upon both the body burden of
aluminium and the location of significant deposits of
aluminium. It is not yet clear which form or forms
of aluminium are capable of acting as antigens [30]. If
Al3+(aq) is the antigen then this could help to explain why
the body isn’t (presumably) on continuous immune alert
against its everyday burden of aluminium. The concentra-
tion of Al3+(aq) in the majority of physiological milieu will
be nanomolar [27] and its propensity to act as an antigen
will depend upon the kinetic inertia of deposits of alu-
minium in delivering Al3+(aq) at a rate sufficient to fuel
the formation of antibodies against it. Such situations
could include sites of injection of aluminium adjuvants,
the lymph nodes and known targets of aluminium in
the brain including myelin.Aluminium as a potent adjuvant
Another situation which might help to explain the puta-
tive toxicity of aluminium adjuvants in allergy immuno-
therapies and vaccinations is the outcome of the known
potency of aluminium salts as adjuvants. Aluminium
salts are not only effective in increasing the antigenicity
of the allergens and antigens which are the targets of
therapies they are also able to induce antigenicity in
substances which would not otherwise act as antigens
or allergens [31]. One example of this is to induce allergy
to codfish by feeding mice with codfish and aluminium
antacids [32]. Within a relatively short period of time
the mice are demonstrating allergic responses to codfish
alone. The potency of aluminium salts as adjuvants must
be carefully considered in the preparation of allergy im-
munotherapies as any additional components or con-
taminants of the injections [33] could become antigenic
and the target of an immune response both at the injec-
tion site and even beyond at other places in the body.
The adjuvanticity of aluminium salts may also come
into play in inducing antigenicity in constituents of
foreign- or self-origin in the vicinity of the injection
site. Actually such a mechanism may have a role to play
in the efficacy of aluminium adjuvants in immunopo-
tentiation though ideally these effects should not be
translated elsewhere in the body where such would be
unwanted and potentially toxic.
Aluminium adjuvants in allergy immunotherapy need to
be both effective and safe
Aluminium is an effective adjuvant in allergy immuno-
therapy because of its biological reactivity and that same
reactivity means that there must be a number of mecha-
nisms whereby aluminium adjuvants could also result in
adverse events. One or more of these mechanisms could
be a component of the, as yet non-elucidated, mode of
action of aluminium adjuvants in stimulating or modify-
ing immunity and in the majority of recipients of allergy
therapies will result in little or limited discomfort. How-
ever, the likelihood is that each of these mechanisms will
play some role, to a lesser or greater extent, in an indi-
vidual’s response to the injection of aluminium adjuvant
and in some individuals or particular circumstances the
biological response to one or repeated injections of alu-
minium salt will be an adverse event. The difficulty is in
predicting which individual or what set of circumstances
is likely to instigate a biological cascade leading to tox-
icity. One probable predisposition would be an unusually
high body burden of aluminium. There are many pos-
sible reasons why an individual’s body burden of alumin-
ium is high including exposure to aluminium through
extended periods of sub-cutaneous immunotherapy. Re-
search is on-going into the best way of establishing by
non-invasive means an individual’s body burden of
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urinary excretion of aluminium [14,26]. Future research
should elaborate upon whether individuals with high
body burdens of aluminium are more likely to suffer an
adverse reaction to immunotherapy as well as whether
individuals receiving extended periods of immunotherapy
are more likely to have higher body burdens of aluminium
and thereby predisposing themselves to an adverse event
in the future.
Conclusions
Aluminium hydroxide is currently the adjuvant of choice
in sub-cutaneous allergy immunotherapy. Aluminium
adjuvants are used to modify the immune response to a
range of allergens and are generally used in multiple
injections over extended time periods. Adverse events or
reactions to allergy immunotherapy are documented and
have been associated with aluminium adjuvants. While
the mechanism of action of aluminium adjuvants in im-
munotherapy (likewise vaccination) has not been fully
elucidated it will be allied to the biological reactivity of
aluminium at both the injection site and elsewhere in
the body. Adverse reactions to aluminium adjuvants may
be amplifications of aluminium’s activity as an adjuvant
and there may be subsets of individuals who are predis-
posed to such events. For example, individuals with a high
body burden of aluminium, to which allergy immunother-
apy will be a contributor, may be more susceptible to ad-
verse events. There are few reliable data purporting to
neither the safety nor the toxicity of aluminium adjuvants
used in allergy immunotherapy. These gaps in knowledge
should be remedied in future clinical trials of new im-
munotherapies and in records of clinical practice of
therapies currently in use.
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